Prof. Dr. med. Wolfgang Sauerwein

M.D., Ph.D., FASTRO. He completed his residency in Radiation Medicine at MGH, Harvard Medical School, and until 2003 was lead physician and Principal Investigator for the Harvard MIT BNCT Program. Chief of the Head and Neck Service and Clinical Director in the Department of Radiation Oncology at MGH, and a member of the NCCN Head and Neck Panel. Recognised as an ASTRO Fellow in 2018, an honor held by fewer than 3 percent of the membership.

MD in Radiation Oncology and PhD in Nuclear Physics from Strasbourg University, on neutron capture therapy. He began at the Centre Antoine Lacassagne in Nice and the Institut Gustave Roussy in Paris and served as secretary to the EORTC BNCT Group. Former Professor and Chair of Radiation Oncology at Erasmus MC Rotterdam and medical co director of HollandPTC. In 2021 he joined Accuray as Senior Vice President and Chief Medical and Technology Officer.

Physics diploma from the University of Dortmund and a doctorate in medicine from the University of Cologne, with a residency in radiology and radiation oncology at Hannover Medical School. After more than 20 years of medical practice in proton therapy, a Full Professor at Loma Linda University. He develops novel instrumentation and algorithms for proton therapy and promotes a new era of neutron capture therapy at his university and beyond.

Clinical Professor at the University of Illinois College of Medicine Peoria and Chief Medical Officer at ART and Integrated Proton Solutions. Former Director of Proton Therapy at the University of Miami Sylvester Comprehensive Cancer Center and former Chief of GI, Lung and Breast at the Scripps Proton Therapy Center. Co editor in chief of Translational Cancer Research. He completed the M.D. Ph.D. Medical Scientist Training Program with a PhD in Medical Physics at UT MD Anderson Cancer Center in 1994.

Director of Research of the CNRS at the Institute for Advanced Biosciences in Grenoble, leading the Translational Theranostic Team. Her work develops nano agents for cancer imaging and therapy, in particular for BNCT, and image guided surgery, with translational work taken into clinical trials. Author of more than 120 communications, holder of 5 patents and co founder of 3 start ups. President of the SFNano board, the French Society of Nanomedicine, and a member of the German BNCT Society.

Ph.D. researching DNA damage response, radiation biology and cancer treatment including BNCT. Coordinator of the Japanese Society of Neutron Capture Therapy and former head of the Division of Genome Stability Research at the National Cancer Center Research Institute in Tokyo. She led the preclinical research at the BNCT facility of the National Cancer Center Hospital toward permission to treat patients there.

Eiji Matsuura graduated from Okayama University Graduate School of Pharmaceutical Sciences and earned his PhD from Okayama University Graduate School of Medicine. After research posts in Denver, at Yamasa Corporation and at Hokkaido University, he returned to Okayama in 1997 as a professor at its Collaborative Research Center and Neutron Therapy Research Center. Now Professor Emeritus and Special Appointed Professor, his work spans cancer and autoimmune pathophysiology, drug delivery systems for BNCT, and molecular imaging and theranostics. He is co founder and Managing Director of Cardiovascular Solutions and Innovations LLC in the United States and CEO of CSI Global Health, an Okayama University start up.

Professor of Inorganic Chemistry at Leipzig University from 1993 to 2023, now at its Institute of Bioanalytical Chemistry. A Fellow of the Royal Society of Chemistry and member of Academia Europaea, with awards including the IUPAC Distinguished Woman in Chemistry Award and the Karl Ziegler Prize. She has published more than 650 articles and supervised over 100 doctoral graduates, and is Vice President of the German Society on Boron Neutron Capture Therapy. Her focus is biologically active boron and metal compounds for medicinal use.

Director of Research Emeritus at CNRS-IN2P3 and Grenoble-Alpes University, heading a platform on directional dark matter search, fast neutron spectroscopy and accelerator based neutron capture therapy at the Laboratory of Subatomic Physics and Cosmology. He previously managed the sorption cooler electronics for the Planck space mission. An expert on neutron dosimetry and field characterisation, he has supervised 15 PhD theses.

Founder and CTO of Cosmic Shielding Corporation, Director of the CRREAT project at the Nuclear Physics Institute of the Czech Academy of Sciences, and Professor at Chalmers University of Technology. Former Head of Nuclear Science and Engineering at Chalmers and former Head of the Department of Radiation Physics at TU Wien, where he also led applied medical physics research at the MedAustron ion beam therapy center. Four decades in medical radiation physics, with collaborations across NASA, ESA and JAXA.

Dr.-Ing. with deep expertise in radiation transport calculations using Monte Carlo and deterministic codes, applied to licensing, decommissioning and optimised shielding for radioactive nuclides used in cancer therapy. More than 25 years in leading positions in nuclear service and power generation, with international projects across India, Turkey, the UK, Ireland, the US and Brazil. She earned her PhD by designing an irradiation facility for BNCT on autotransplanted organs, and since 2018 works independently as a consultant, lecturer and invited expert for the European Commission.

Professor Emeritus at the University of Wisconsin-Madison and a serial entrepreneur. Co founder of TomoTherapy, of HealthMyne, and of Leo Cancer Care, and co founder of Geometrics Corporation, whose Pinnacle treatment planning system became one of the largest selling in the world. Commissioner and Vice Chair of the ICRU. Awarded the ASTRO Gold Medal in 2019 for his service to radiation oncology.

A seasoned executive in the global radiotherapy industry with over three decades of experience. He held senior executive roles in the Oncology Systems business of Varian Medical Systems, now part of Siemens Healthineers. He is founder and president of Staila Polaris MedTech GmbH, a Swiss consulting firm supporting clinical and industry clients in market development, access, marketing and sales in radiotherapy, and is committed to accelerating the clinical adoption of BNCT.

Founder and President of EURO-JAPAN Corporate Advisors Inc., a consulting firm for business and market entry between Japan, Europe and the United States. He formerly headed NRW Japan K.K., the Japan office of the trade and investment agency of North Rhine-Westphalia, after senior banking roles in Germany, Japan, Indonesia and China. He focuses on startups and businesses in energy, sustainability and medtech, and studied economics and Japanese studies in Tübingen, Berlin and Tokyo.

Attorney at law and venture investor in Berlin, running Oceanview Capital, advising family offices and mid size corporates on innovation and investment strategy. From 2007 to 2020 a Senior Vice President at DPDHL Group, where he built the corporate incubations department and the international ecommerce operations for DHL Globalmail from Singapore and Tokyo. He holds an MBA from the Graduate School of Business in Cape Town and studied at the Anderson School at UCLA.

Florian Husen is the founder and CEO of MANERI, a venture builder that develops brands in AI and digital marketing, including the agency x10a. He advises medical and research organisations on building their digital presence and lectures on digitalisation for medical practices at the Zahnärztekammer Bremen. He created and manages the BNCT Global website.